Trial of Best Available Therapy versus Autologous Hematopoietic Stem Cell Transplant for Treatment-Resistant Relapsing Multiple Sclerosis

Trial of Best Available Therapy versus Autologous Hematopoietic Stem Cell Transplant for Treatment-Resistant Relapsing Multiple Sclerosis
Recruiting
18 years - 99 years
All
Phase N/A
4 participants needed
1 Location

Brief description of study

The purpose of this study is to compare efficacy and safety of Autologous Hematopoietic Stem Cell Transplant (AHSCT) to best available therapy (BAT) in relapsing MS. Best available therapy is referring to the best available medications that are used to treat MS. Patients who agree to participate in the experimental treatment study will be randomly chosen (like a coin flip) to have an AHSCT or BAT. Neither you nor your doctor are able to decide which treatment you will receive. In addition, patients interested in participating must have permission from their insurance company to enter the trial.

Eligibility of study

You may be eligible for this study if you meet the following criteria:

  • Conditions: Multiple Sclerosis
  • Age: 18 years - 99 years
  • Gender: All


Updated on 19 Feb 2024. Study ID: 842819

Find a site

Message sent successfully.
We have submitted the information you provided to the research team at the location you chose. For your records, we have sent a copy of the message to your email address.
If you would like to be informed of other studies that may be of interest to you, you may sign up for Patient Notification Service.
Sign up

Send a message

Enter your contact details to connect with study team

Email

View email

Phone

Phone country flag

View phone
Investigator Avatar

Primary Contact

First name*
Last name*
Email*
Phone number*
Preferred way of contact
Race
Ethnicity
Other language

Message For Non Enrolling By Invitation Trial

Select a study center that’s convenient for you, and get in touch with the study team.